Hematopoietic cell transplantation for sialidosis type I

Area of Science:

• Biochemistry
• Genetics
• Hematology

Background:

• Sialidosis is a rare lysosomal storage disorder.
• Type I Sialidosis presents with progressive neurological decline.
• Limited treatment options exist for Sialidosis.

Purpose of the Study:

• To report the clinical and laboratory outcomes of a patient with Type I Sialidosis who received a bone marrow transplant (BMT).
• To evaluate the efficacy of BMT in addressing the biomarkers and clinical manifestations of Type I Sialidosis.
• To present the first documented case of BMT for Type I Sialidosis.

Main Methods:

• Clinical data collection and laboratory biomarker analysis pre- and post-BMT.
• Monitoring of engraftment following bone marrow transplantation.
• Neuropsychiatric and motor performance assessments.

Main Results:

• Concurrent improvement in plasma and urine biomarkers with successful engraftment post-BMT.
• Preservation of some neuropsychiatric functions observed.
• A notable decline in overall motor performance was recorded.

Conclusions:

• Bone marrow transplant may positively impact Sialidosis biomarkers.
• BMT in Type I Sialidosis shows a complex clinical response, with preserved cognition but impaired motor function.
• This case represents a novel therapeutic approach for a rare lysosomal disorder, highlighting the need for further research.